Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: postoperative adjuvant therapy.
- Who it may be relevant to
- Registry conditions: Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study
Overview
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
Interventions
- Procedure postoperative adjuvant therapy
Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
Primary outcome measures
- Disease-free survival [Time frame: From December 2018 to May 2023]
Secondary outcome measures (1)
- Overall survival [Time frame: From December 2018 to May 2023]
Eligibility criteria
Inclusion criteria
- patients who underwent liver resection
- patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
Exclusion criteria
- patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
- patients diagnosed with other specific types of sarcomas;
- patients with concurrent other malignancies during the course of PHSC;
- patients who were lost to follow-up or lacked essential clinical data.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- West China Hospital — Chengdu
Identifiers
NCT: NCT06950814 · JHuang20231